A Phase 3b study of DE-089C ophthalmic solution in subjects with Dry eye

A phase 3b, randomized, multicenter, open label, crossover study: To compare patient adherence and compliance between to DE-089C and DIQUAS in subjects with Dry eye.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080225370

Enrollment

Registered

2020-08-28

Start date

2020-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry eye

Interventions

investigational material(s) Generic name etc : Diquafosol Sodium INN of investigational material : diquafosol Therapeutic category code : 131 Agents for ophthalmic use Dosage and Administration for In

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Outpatients - Both eyes diagnosed as having Dry eye

Exclusion criteria

Exclusion criteria: - Ocular disease which needs treatment except Dry eye - Allergic conjunctivitis which has fear of worsen during the study and considered unsuitable for the study by the investigators - Anyone otherwise considered unsuitable for the study by the investigators

Design outcomes

Primary

Measure	Time frame
other Evaluation with patients answer to questionnaire - To compare the compliance to instillation of DE-089C and DIQUAS ophthalmic solution - To compare the adherence to instillations of DE-089C and DIQUAS ophthalmic solution	—

Secondary

Measure	Time frame
other - To investigate the continuity of instillation - To investigate the compliance, burden and influence factors on continuity with instillation	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026